Cancer Immunology Reserch

Cancer Immunol Res. 2026 Aug 4. doi: 10.1158/2326-6066.CIR-25-1285. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key … Read more

Cancer Immunol Res. 2026 Aug 4;14(8):1209. doi: 10.1158/2326-6066.CIR-14-8-WWR. NO ABSTRACT PMID:42548193 | DOI:10.1158/2326-6066.CIR-14-8-WWR

Cancer Immunol Res. 2026 Jul 31. doi: 10.1158/2326-6066.CIR-25-1639. Online ahead of print. ABSTRACT Immune checkpoint inhibitor (ICI) therapy is often associated with immune-related adverse events including inflammatory arthritis (ICI-IA). However, the mechanisms underlying ICI-IA, especially its recurrence, are not well understood. In this study, we sought to elucidate mechanisms of recurrent ICI-IA by analyzing longitudinal … Read more

Cancer Immunol Res. 2026 Jul 24. doi: 10.1158/2326-6066.CIR-25-1481. Online ahead of print. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) exhibits dense fibrosis and immune exclusion. While fibrosis has been studied globally and at the region-of-interest level, its impact on stromal-ductal architecture and immune cell localization remains unknown. Here, we establish cancer-associated fibroblast (CAF)-stratified ductal spatial architecture as … Read more

Cancer Immunol Res. 2026 Jul 22. doi: 10.1158/2326-6066.CIR-25-1230. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR)-T cell therapy has become a promising clinical approach against hematological malignancies, but patients receiving CAR-T cell therapy still presented inconsistent clinical outcomes and are complicated by incomplete tumor eradication. The gut microbiome has shown strong correlation with the … Read more

Cancer Immunol Res. 2026 Jul 22. doi: 10.1158/2326-6066.CIR-25-1493. Online ahead of print. ABSTRACT T cell exhaustion remains a barrier to adoptive cell therapies. Although γc cytokines are used to expand T cells, their impact on T cell states remains incompletely defined. Using an in vitro model of repetitive TCR stimulation, we found that high-dose IL-2 … Read more

Cancer Immunol Res. 2026 Jul 16. doi: 10.1158/2326-6066.CIR-25-1652. Online ahead of print. ABSTRACT It is well established that CD4⁺ T cells play a critical role in facilitating immune checkpoint therapy (ICT). Although CD4+ T-cell function in lymph nodes during CD8⁺ T-cell priming has been well investigated, their requirement at the effector phase in the tumor … Read more

Cancer Immunol Res. 2026 Jul 16. doi: 10.1158/2326-6066.CIR-25-1617. Online ahead of print. ABSTRACT In esophageal squamous cell carcinoma (ESCC), chemoradiotherapy potentiates the effects of immune checkpoint inhibitors (ICIs) by activating the tumor-intrinsic innate immune response. However, ESCC cells frequently suppress this activation, which contributes to the high rates of immunotherapy resistance (70-80%) observed clinically. Thus, … Read more

Cancer Immunol Res. 2026 Jul 15. doi: 10.1158/2326-6066.CIR-25-0687. Online ahead of print. ABSTRACT Regulatory T cells (Treg) act as a powerful barrier to effective antitumor immunity. Although manipulating Treg is a promising anticancer strategy, doing so while sparing general immune tolerance has been a challenge. Identifying factors specifically expressed in tumor-infiltrating Treg is therefore important … Read more

Cancer Immunol Res. 2026 Jul 14. doi: 10.1158/2326-6066.CIR-25-0506. Online ahead of print. ABSTRACT Glioblastoma multiforme (GBM) is a lethal brain tumor with limited treatment options. Tumor-associated macrophages and microglia (TAMs) drive immune suppression and tumor progression, making them a key therapeutic target for GBM. Enhancing TAM phagocytosis in GBM has shown promise, particularly with innate … Read more